TVRD logo

TVARDI THERAPEUTICS INC

TVRDNASDAQ
🏆 #4782 by market capEarnings Nov 12US Equity
$0.90▲ $0.03 (+2.95%)
Pre-market · at close
🔔
Track TVRD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.0%
7d▼ 13.0%
14d▼ 15.4%
30d▼ 30.2%
ytd▼ 79.1%
1y▼ 81.0%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.90 – $0.91
52-Week Range
$0.83 – $5.69
Volume (shares)
300
Avg Volume (shares)
—
Shares Outstanding
13.3M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.3
P/S Ratio
0.0x
EPS (TTM)
$-2.79
Dividend Yield
0.00%
Dilution (1yr)
+515.6%
TVRD logo

TVARDI THERAPEUTICS INC

TVRD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.6%▲ +27.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −52.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$23M▼ −62.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.4M▲ +515.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$21M▲ +$27M YoY
StockOtter · stockotter.space

About TVARDI THERAPEUTICS INC

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy4
Buy8
Hold2
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.